董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arie Mayer | 男 | Independent Director | 69 | 21.90万美元 | 13.56 | 2026-09-15 |
| Benjamin Shapiro | 男 | Independent Director | 42 | 20.00万美元 | 196.15 | 2026-09-15 |
| Daniel Aghion | 男 | Independent Director | 44 | 22.86万美元 | 2.88 | 2026-09-15 |
| Yehuda Reznick | 男 | Independent Director | 78 | 22.86万美元 | 4.46 | 2026-09-15 |
| Nadav Kidron | 男 | President, Chief Executive Officer and Chairman | 51 | 477.47万美元 | 341.65 | 2026-09-15 |
| Miriam Kidron | 女 | Chief Scientific Officer and Director | 85 | 216.64万美元 | 148.71 | 2026-09-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nadav Kidron | 男 | President, Chief Executive Officer and Chairman | 51 | 477.47万美元 | 341.65 | 2026-09-15 |
| Miriam Kidron | 女 | Chief Scientific Officer and Director | 85 | 216.64万美元 | 148.71 | 2026-09-15 |
| Joshua Hexter | 男 | Chief Operating and Business Officer | 55 | 188.24万美元 | 109.21 | 2026-09-15 |
董事简历
中英对照 | 中文 | 英文- Arie Mayer
-
Arie Mayer目前是Sigma Aldrich Israel Ltd.的董事总经理兼董事会主席，自2010年1月起担任该职位。Mayer博士自1995年以来一直在Sigma Aldrich Israel Ltd.担任各种职务，并在为Sigma Aldrich Israel Ltd.引进和发展细胞培养和分子生物学业务方面发挥了重要作用。Mayer博士拥有希伯来大学化学理学学士学位和以色列理工学院生物化学博士学位。
Arie Mayer is currently the Managing Director and Chairman of the Board of Sigma Aldrich Israel Ltd. and has held that position since January 2010. Dr. Mayer has held various roles with Sigma Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel Ltd. Dr. Mayer holds a Bachelor of Science degree in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology. - Arie Mayer目前是Sigma Aldrich Israel Ltd.的董事总经理兼董事会主席，自2010年1月起担任该职位。Mayer博士自1995年以来一直在Sigma Aldrich Israel Ltd.担任各种职务，并在为Sigma Aldrich Israel Ltd.引进和发展细胞培养和分子生物学业务方面发挥了重要作用。Mayer博士拥有希伯来大学化学理学学士学位和以色列理工学院生物化学博士学位。
- Arie Mayer is currently the Managing Director and Chairman of the Board of Sigma Aldrich Israel Ltd. and has held that position since January 2010. Dr. Mayer has held various roles with Sigma Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel Ltd. Dr. Mayer holds a Bachelor of Science degree in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology.
- Benjamin Shapiro
-
本杰明·夏皮罗是一位成功的企业家和商业专业人士，他于2015年6月共同创立了The Daily Wire，这是一家成功的、行业领先的国际媒体。自2015年5月以来，他一直担任热门播客节目《The Ben Shapiro Show》的主持人，他是众多《纽约时报》畅销书籍的作者。夏皮罗先生于2004年以优异成绩获得加州大学洛杉矶分校政治学学士学位，并于2007年以优异成绩获得哈佛法学院法学学位。
Benjamin Shapiro is a successful entrepreneur and business professional who co founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he has been host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best selling books. Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree from Harvard Law School in 2007, cum laude. - 本杰明·夏皮罗是一位成功的企业家和商业专业人士，他于2015年6月共同创立了The Daily Wire，这是一家成功的、行业领先的国际媒体。自2015年5月以来，他一直担任热门播客节目《The Ben Shapiro Show》的主持人，他是众多《纽约时报》畅销书籍的作者。夏皮罗先生于2004年以优异成绩获得加州大学洛杉矶分校政治学学士学位，并于2007年以优异成绩获得哈佛法学院法学学位。
- Benjamin Shapiro is a successful entrepreneur and business professional who co founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he has been host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best selling books. Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree from Harvard Law School in 2007, cum laude.
- Daniel Aghion
-
自2016年以来，Daniel Aghion一直是佛罗里达州纪念神经科学研究所的一名神经外科医生，在那里他治疗患有多种脊柱疾病的患者，包括严重的退行性脊柱疾病、脊柱创伤、脊柱癌症、脊柱肿瘤、周围神经手术等等。Aghion博士拥有密歇根大学的理学学士学位和特拉维夫大学萨克勒医学院的医学博士学位。他于2015年完成了在罗德岛医院的住院治疗，并于2016年在巴尔的摩的约翰霍普金斯大学完成了复杂的脊柱研究金。
Daniel Aghion has been a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016. - 自2016年以来，Daniel Aghion一直是佛罗里达州纪念神经科学研究所的一名神经外科医生，在那里他治疗患有多种脊柱疾病的患者，包括严重的退行性脊柱疾病、脊柱创伤、脊柱癌症、脊柱肿瘤、周围神经手术等等。Aghion博士拥有密歇根大学的理学学士学位和特拉维夫大学萨克勒医学院的医学博士学位。他于2015年完成了在罗德岛医院的住院治疗，并于2016年在巴尔的摩的约翰霍普金斯大学完成了复杂的脊柱研究金。
- Daniel Aghion has been a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.
- Yehuda Reznick
-
Yehuda Reznick曾于1999年至2014年担任普华永道国际有限公司成员Kesselman & Kesselman CPA的审计合伙人。在加入Kesselman & Kesselman之前，他是Shachak的税务和审计合伙人，Peer Reznick注册会计师十六年。自2019年以来，Reznick先生还担任Hiron Trade Investments & Industrial Buildings Ltd（TASE：HRON）的董事会成员。Reznick先生曾于2017年至2023年担任Bonus BioGroup Ltd（OTC：BBIXF）的董事会成员。自2026年3月起，Reznick先生还担任Lifeward Ltd.（纳斯达克：LFWD）的董事会成员。
Yehuda Reznick served as an audit partner at Kesselman & Kesselman CPA, a member of PricewaterhouseCoopers International Limited, from 1999 until 2014. Prior to joining Kesselman & Kesselman, he was a tax and audit partner at Shachak, Peer Reznick CPA for sixteen years. Since 2019, Mr. Reznick has also served on the board of directors of Hiron Trade Investments & Industrial Buildings Ltd (TASE: HRON). Mr. Reznick previously served on the board of directors of Bonus Biogroup Ltd (OTC: BBIXF) from 2017 to 2023. Since March 2026, Mr. Reznick has also served on the board of directors of Lifeward Ltd. (Nasdaq: LFWD). - Yehuda Reznick曾于1999年至2014年担任普华永道国际有限公司成员Kesselman & Kesselman CPA的审计合伙人。在加入Kesselman & Kesselman之前，他是Shachak的税务和审计合伙人，Peer Reznick注册会计师十六年。自2019年以来，Reznick先生还担任Hiron Trade Investments & Industrial Buildings Ltd（TASE：HRON）的董事会成员。Reznick先生曾于2017年至2023年担任Bonus BioGroup Ltd（OTC：BBIXF）的董事会成员。自2026年3月起，Reznick先生还担任Lifeward Ltd.（纳斯达克：LFWD）的董事会成员。
- Yehuda Reznick served as an audit partner at Kesselman & Kesselman CPA, a member of PricewaterhouseCoopers International Limited, from 1999 until 2014. Prior to joining Kesselman & Kesselman, he was a tax and audit partner at Shachak, Peer Reznick CPA for sixteen years. Since 2019, Mr. Reznick has also served on the board of directors of Hiron Trade Investments & Industrial Buildings Ltd (TASE: HRON). Mr. Reznick previously served on the board of directors of Bonus Biogroup Ltd (OTC: BBIXF) from 2017 to 2023. Since March 2026, Mr. Reznick has also served on the board of directors of Lifeward Ltd. (Nasdaq: LFWD).
- Nadav Kidron
-
Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
Nadav Kidron is also Chairman of the board of MDG Real Estate Global, Ltd., director of Alpha Tau Medical Ltd., director of Lifeward Ltd. (Nasdaq: LFWD) since March 2026, director of Israel Advanced Technology Industries organization and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S. Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel. - Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
- Nadav Kidron is also Chairman of the board of MDG Real Estate Global, Ltd., director of Alpha Tau Medical Ltd., director of Lifeward Ltd. (Nasdaq: LFWD) since March 2026, director of Israel Advanced Technology Industries organization and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S. Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.
- Miriam Kidron
-
Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
Miriam Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. Since March 2026, Dr. Kidron has served as a director of Lifeward Ltd. (Nasdaq: LFWD). - Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
- Miriam Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. Since March 2026, Dr. Kidron has served as a director of Lifeward Ltd. (Nasdaq: LFWD).
高管简历
中英对照 | 中文 | 英文- Nadav Kidron
Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
Nadav Kidron is also Chairman of the board of MDG Real Estate Global, Ltd., director of Alpha Tau Medical Ltd., director of Lifeward Ltd. (Nasdaq: LFWD) since March 2026, director of Israel Advanced Technology Industries organization and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S. Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.- Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
- Nadav Kidron is also Chairman of the board of MDG Real Estate Global, Ltd., director of Alpha Tau Medical Ltd., director of Lifeward Ltd. (Nasdaq: LFWD) since March 2026, director of Israel Advanced Technology Industries organization and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S. Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.
- Miriam Kidron
Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
Miriam Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. Since March 2026, Dr. Kidron has served as a director of Lifeward Ltd. (Nasdaq: LFWD).- Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
- Miriam Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. Since March 2026, Dr. Kidron has served as a director of Lifeward Ltd. (Nasdaq: LFWD).
- Joshua Hexter
Joshua Hexter， 于2013年4月被任命为首席运营官和商业开发副总裁。2007-2013年期间，在一家致力于识别、授权和开发创新疗法药物的生物医药开发公司- BioLineRx有限公司“BioLine”（TASE： BLRX）的一位董事或者执行董事。在BioLine任职之前，他曾是一家发展市场导向生物感测器的公司- Biosensor Systems Design股份有限公司的一位董事会成员和首席执行官。他拥有Wisconsin大学的学士学位，以及波士顿大学（Boston University）的管理学硕士学位。
Joshua Hexter has been affiliated with Oramed since 2013, initially serving as Chief Operating Officer and VP Business Development from 2013 to 2018, and returning to the Company in his current role in 2019. In the intervening period, Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (Nasdaq/TASE: BWAY) from 2018 to 2019, a commercial stage medical device company focused on the development and sale of non invasive neuromodulation products. Prior to that, Mr. Hexter was Executive Director at BioLineRx Ltd. (Nasdaq/TASE: BLRX) from 2007 to 2013, a biopharmaceutical development company dedicated to identifying, in licensing and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market driven biosensors. Mr. Hexter holds a bachelor's degree from the University of Wisconsin and a master's degree in management.- Joshua Hexter， 于2013年4月被任命为首席运营官和商业开发副总裁。2007-2013年期间，在一家致力于识别、授权和开发创新疗法药物的生物医药开发公司- BioLineRx有限公司“BioLine”（TASE： BLRX）的一位董事或者执行董事。在BioLine任职之前，他曾是一家发展市场导向生物感测器的公司- Biosensor Systems Design股份有限公司的一位董事会成员和首席执行官。他拥有Wisconsin大学的学士学位，以及波士顿大学（Boston University）的管理学硕士学位。
- Joshua Hexter has been affiliated with Oramed since 2013, initially serving as Chief Operating Officer and VP Business Development from 2013 to 2018, and returning to the Company in his current role in 2019. In the intervening period, Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (Nasdaq/TASE: BWAY) from 2018 to 2019, a commercial stage medical device company focused on the development and sale of non invasive neuromodulation products. Prior to that, Mr. Hexter was Executive Director at BioLineRx Ltd. (Nasdaq/TASE: BLRX) from 2007 to 2013, a biopharmaceutical development company dedicated to identifying, in licensing and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market driven biosensors. Mr. Hexter holds a bachelor's degree from the University of Wisconsin and a master's degree in management.